Science and Partners

Impact of Alzheimer’s and other cognitive disorders in Canada


Aging of the population and growth in cognitive disorders

An estimated 564,000 Canadians were living with dementia in 2016, of which Alzheimer’s disease (AD) was the most common type.

Canada’s population is aging rapidly; 25,000 new cases of dementia are diagnosed every year.

The number of cases of dementia is expected to rise to 937,000 by 2031, an increase of 66%.


Impact on those living with AD and their loved ones

AD and related conditions have a serious and dramatic impact on the lives of all those affected. It is estimated that 1.1 million Canadians are directly or indirectly affected by this devastating disease.

Recent data shows that the majority (87%) of those caring for someone with Alzheimer’s disease want their reality to be better understood and 2/3 of them find that the challenges they face as caregivers lead to a sense of isolation.


Impact on our healthcare system

Dementia is a major economic burden on the Canadian healthcare system. In fact, the annual cost to Canadians caring for those afflicted is estimated to be $10.4 billion.

There are currently 56,000 Canadians being treated for dementia in hospitals, which are widely recognized as being less than ideal settings for appropriate care.

Source: Alzheimer Society of Canada


Healthy lifestyles as a preventive measure

There is currently no cure for Alzheimer’s disease nor for its related diseases.

Despite that fact, science confirms that over 30% of AD cases are attributable to modifiable risk factors.

The message is clear: approaches focused on adopting and maintaining healthy lifestyles represent a potentially effective way for preventing or delaying cognitive decline and dementia.

Luci is being developed to harness this powerful preventive approach. Building on theories of behavioral change, our team of healthy lifestyle advisors (see below) supports users who want to adopt healthy lifestyle habits in three areas of life: diet, physical activity and intellectual stimulation.

Scientific committee

One of Luci's prime objectives is to advance scientific knowledge in the area of cognitive prevention decline.

Our process for scientifically validating Luci was established jointly with a scientific committee made up of 6 senior researchers:

Sylvie Belleville, Ph. D

Dr. Sylvie Belleville is a tenured Professor of Psychology at the Université de Montréal and the Research Director of the Institut Universitaire de Gériatrie de Montréal (IUGM). She is also the Canada Research Chair in Cognitive Neuroscience of Aging and Brain Plasticity, The Director of the Consortium for the early identification of AD-Quebec (CIMA-Q), and the Team Leader of the Canadian Consortium on Neurodegeneration in Aging (CCNA) Cognitive Intervention, Reserve and Brain Plasticity. Dr. Belleville is the President of Luci’s scientific committee.

Michel Boivin, MD

Dr. Boivin is a gastroenterologist at CHUM St-Luc and a tenured Professor at the Université de Montréal Faculty of Medicine. In addition to his medical practice, Dr. Boivin has participated in numerous national and international research protocols. A renowned leader in public health intervention, he contributed to the launch of Passeport Santé website and is the Scientific Director of L’Appui pour les proches aidants d’aînés.

Guy Paré, Ph. D

Guy Paré is the Director of the Ph.D in Administration program and the Research Chair in Digital Health at HEC Montréal. His research has led to numerous scientific publications, expertise reports and conferences. His expertise is valued by several influential international organizations, including the World Health Organization.

Simon L. Bacon, Ph. D, FTOS, FCCS, FABMR

Dr. Bacon is a Professor in the department of Health, Kinesiology, and Applied Physiology (HKAP) at Concordia University. He is also the CIHR SPOR Chair in Innovative, Patient-Oriented, Behavioural Clinical Trials, the FRQS Chair in Behavioural Medicine, the Co-Director of the Montreal Behavioural Medicine Centre, a researcher at the CIUSS-NIM, and the Co-Director for International Behavioural Trials Network (IBTN).

Kim Lavoie, Ph.D, FCPA, FABMR

Dr. Lavoie is the Co-Director of the Montreal Behavioural Medicine Centre (MBMC) and Co-Lead of the International Behavioural Trials Network (IBTN). She is a tenured Professor, the chair of Behavioral Medicine, and an ERQS Senior Research Fellow at UQAM’s Department of Psychology. She is also the program Chair, Health Psychology and Behavioral Medicine Section, of the Canadian Psychological Association and an active member of the Canadian Hypertension Education Program (CHEP) recommendation subcommittee.

Guylaine Ferland, Ph.D

Guylaine Ferland is a tenured Professor in the Department of Nutrition at the Université de Montréal, a researcher at the Montreal Heart Institute, and an Associate Researchers at the Institut universitaire de gériatrie de Montréal (IUGM). In addition to being actively involved in various research activities, Dr. Ferland is the President of the Canadian Nutrition Society. Her work focuses on identifying the determinants of nutrition on the status of seniors living in geriatric settings.

Scientific studies

Luci will undergo clinical validation using 3 distinct studies: proof of concept, feasibility and effectiveness.

If you’re between the ages of 50 and 70, and would like to make an important contribution to this field of study, we invite you to take part.

Are you between the ages of 50 and 70? Contact us to add your name to our databank of Luci testers

Contact us

Our partners

One of Luci’s key objectives is to help further scientific knowledge in the prevention of cognitive decline.